查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1390428

2023-2028年按类型、药物类别（缓解疾病抗风湿药、非类固醇类抗发炎药、皮质类固醇、尿酸药物等）、药物管理、配销通路和地区的抗风湿药市场报告

Anti-Rheumatics Market Report by Type, Drug Class (Disease Modifying Anti-Rheumatics Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others), Drug Administration, Distribution Channel, and Region 2023-2028
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

抽象的

2022年全球抗风湿药市场规模达628亿美元。展望未来， IMARC Group预计到2028年市场规模将达到739亿美元，2022-2028年复合年增长率（CAGR）为2.75%。全球人口老化加剧，医院、诊所和其他医疗机构的扩张，以及大型製药公司和医疗中心之间不断扩大的合作伙伴关係是推动市场成长的一些主要因素。

抗风湿药是用来治疗影响关节、肌肉和结缔组织的疾病的药物。它们有助于减轻发炎、疼痛和僵硬，并减缓疾病的进展。它们有多种类别，包括非类固醇抗发炎药 (NSAID)、缓解疾病抗风湿药 (DMARD) 和生物製剂。它们可以透过口服、皮下和静脉注射进入体内。它们针对导致组织损伤和发炎的潜在机制。它们通常在彻底诊断后开出处方，并结合使用以获得最佳效果。

由于不健康的饮食模式和缺乏体力活动导致风湿病患病率不断上升，这是促进有效治疗需求的关键因素之一。此外，药物传输系统（例如基于奈米颗粒的载体或缓释胶囊）的持续发展正在增强抗风湿药物的功效和便利性。除此之外，远距医疗服务的成长使得更好的疾病管理和更容易的处方补充成为可能，从而促进抗风湿药物的持续使用。此外，医疗保健系统向新兴市场的扩张使得服务不足的人群更容易获得抗风湿药物。此外，基因组学和个人化医疗的进步使得更有针对性的治疗成为可能，并提高了抗风湿药物的有效性。

抗风湿药市场趋势/驱动因素：

人口老化加剧

人口老化加剧，更容易患骨关节炎和类风湿性关节炎等关节疾病，这是促进市场成长的关键因素之一。此外，老年族群往往有多种健康状况，可能会加剧风湿性疾病，因此需要更复杂和长期的治疗策略。此外，各国的管理当局和医疗保健系统正在认识到这一日益增长的需求，并正在增加医疗保健预算，以应对老龄化社会的挑战。製药公司也将研发工作重点放在创造更有效、更安全的抗风湿药物。因此，这些药物的市场预计在未来几年将大幅成长。

策略合作与合併

製药公司和医疗保健机构之间的策略合作、併购（M&A）数量不断增加是推动市场成长的另一个主要因素。它们通常包括知识共享协议，从而更容易克服监管障碍并缩短新药物的上市时间。此外，大型製药公司和生技新创公司之间不断扩大的合作伙伴关係导致新型抗风湿药物的开发和商业化更快。除此之外，它还促进研发（R&D）活动，以推出更先进的药物。此外，这些合作促进了抗风湿药物的轻鬆供应，以进入以前未开发的市场，从而促进全球市场的成长。

提高早期诊断和预防意识

人们对早期诊断和预防类风湿病的好处的认识不断提高，这正在加强市场的成长。早期诊断可以更有效地治疗该疾病，通常需要使用抗风湿药物。此外，人们越来越依赖社群媒体管道来促进医学教育，这对市场产生了积极影响。此外，一些国家的管理当局正在组织公共卫生运动，这提供了良好的市场前景。此外，先进诊断工具的发展使医疗保健专业人员更容易在早期发现风湿性疾病。这种积极主动的方法增加了抗风湿药物的市场需求，因为及时介入需要药物来控制症状和改变疾病。

抗风湿药产业细分：

IMARC Group提供了对市场报告各细分市场主要趋势的分析，以及 2023 年至 2028 年全球区域和国家层级的预测。我们的报告根据类型、药物类别、给药途径和配销通路对市场进行了分类。

按类型划分：

处方药

非处方药物

处方药占大部分市场份额

该报告根据类型提供了详细的市场细分和分析。这包括处方药和非处方药。该报告称，处方药占据了最大的份额，因为与非处方药 (OTC) 相比，它们通常更有效、更有针对性。此外，处方药通常更有可能被保险计划承保，从而使更多患者群体在经济上负担得起。处方药保险索赔的便利性进一步促进了其使用并有助于扩大其市场份额。除此之外，它们还具有定期医疗保健提供者审查的优势，可以根据疾病的病程和患者的反应不断调整治疗方案。此外，抗风湿治疗的最新创新通常是专利处方药。製药公司大力投资研发以开发新型处方药，确保最先进的治疗方案主要以处方形式提供。

按药物类别细分：

疾病缓解抗风湿药物 (DMARD)

非类固醇类抗发炎药 (NSAID)

皮质类固醇

降尿酸药物

其他的

疾病缓解抗风湿药物（DMARD）在业界占有最大份额

报告还提供了基于药物类别的详细市场细分和分析。这包括缓解病情抗风湿药 (DMARD)、非类固醇类抗发炎药 (NSAID)、皮质类固醇、降尿酸药物等。根据该报告，疾病缓解抗风湿药物 (DMARD) 占了最大的市场份额，因为它们在细胞层面发挥作用，调节免疫反应并有助于有效改变风湿病的病程。此外，它们还有助于减少医院就诊、手术和其他昂贵的医疗干预的频率。除此之外，在许多医疗保健系统中，DMARD 被纳入保险范围计划中，使更多人在经济上负担得起。有效的报销政策进一步鼓励DMARD的处方，从而提高其市场份额。此外，个人化医疗的不断进步正在导致更具针对性的DMARD疗法的开发，提高其疗效并减少潜在的副作用，从而巩固其市场主导地位。

依给药途径细分：

口服

注射用

其他的

注射剂代表领先的细分市场

该报告根据给药途径对市场进行了详细的细分和分析。这包括口服、肠胃外和其他。根据该报告，肠胃外给药是最大的细分市场，因为它可以绕过胃肠道系统，将药物直接输送到血液或目标组织。与口服药物相比，这可以更快起效并且通常提高疗效，这是治疗风湿病急性发作或严重病例的关键因素。除此之外，医生通常更喜欢肠外给药，因为其作用迅速，特别是在需要立即缓解症状或控制疾病的医院环境中。此外，肠外药物经过严格的品质控制措施，以确保无菌和效力，这为医疗保健提供者和患者增加了另一层保证。此外，许多肠胃外製剂均采用预充填注射器或自动注射器，使患者更容易自行给药，进而提高对治疗计画的遵从性。

按配销通路划分：

医院药房

零售药局

电子商务

医院药局市场主导地位明显

报告还根据配销通路对市场进行了详细的细分和分析。这包括医院药房、零售药房和电子商务。报告称，医院药房占据了大部分市场份额，因为它们通常靠近诊间、诊断服务和治疗区域。这种集中化允许在诊断或处方修改后立即配发抗风湿药物，与零售或线上药局相比，在便利性和速度方面具有优势。此外，医院的药剂师通常接受过治疗慢性疾病（包括风湿病）的专门训练和经验。他们与包括风湿病专家和护士在内的医疗团队密切合作，确保患者获得最适合其病情的药物。除此之外，他们全天候运作，确保在紧急情况或非工作时间提供药物。

按地区划分：

北美洲

美国

加拿大

亚太

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美市场领先，占最大的抗风湿药市场份额

市场研究报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美占据了最大的市场份额，因为该地区是药品研发（R&D）中心。此外，北美，特别是美国，拥有完善的医疗保健系统，配备最先进的医疗设施。这种优越的基础设施可以实现风湿性疾病的早期诊断和综合治疗，这自然会导致对抗风湿药物的更高需求。除此之外，专业风湿病诊所和医疗专业人员的广泛使用进一步推动了对这些药物的需求。除此之外，以美国食品药物管理局 (FDA) 等机构为主导的北美监管环境非常支持医疗进步。此外，该地区人口老化的加剧正在推动抗风湿药物的需求。

竞争格局：

公司正大力投资开发新型抗风湿药物，针对现有和新兴的治疗机制。此外，许多公司正在建立合作伙伴关係、併购和收购。这些策略合作通常涉及共享技术、资源和市场管道。除此之外，他们也专注于透过各种管道扩大市场准入。这通常涉及在新的地域市场推出产品、提高生产能力或实现供应链多元化以确保更可靠的分销。此外，各种公司正在使用分析来确定市场趋势、患者偏好和治疗结果。此外，他们还投资于医疗保健提供者、患者和公众的教育计画。

市场研究报告对竞争格局进行了全面分析。也提供了所有主要公司的详细资料。市场上的一些主要参与者包括：

艾伯维公司

安进公司

阿斯特捷利康公司

百健公司

百时美施贵宝公司

赛特瑞恩公司

礼来公司

F.霍夫曼-拉罗氏股份公司

强生公司

辉瑞公司

赛诺菲公司

（请注意，这只是关键参与者的部分列表，报告中提供了完整列表。）

最近的发展：

2023 年7 月，艾伯维公司宣布，第3 期Step-Up HS 研究已对第一位患者进行了给药，该研究旨在评估upadacitinib (RINVOQ (R)) 对患有中度至重度化脓性汗腺炎(HS) 症状的成人和青少年的疗效，但失败了抗肿瘤坏死因子 (TNF) 疗法和一种批准的非抗 TNF 抑制剂疗法治疗 HS.1

2022 年 11 月，安进公司 (Amgen Inc.) 宣布，将在年度美国风湿病学会会展 (ACR) 上展示其广泛的既定治疗组合和管道资产的临床和真实资料。

2022 年9 月，Biogen Inc. 宣布欧洲药品管理局(EMA) 已接受BIIB800 的营销授权申请(MAA)，BIIB800 是一种生物相似药候选药物，参考抗白细胞介素6 受体单株抗体RoACTEMRA ( R)1（托珠单抗） 。

本报告回答的关键问题

  • 2022年全球抗风湿药市场规模是多少
  • 2023-2028年全球抗风湿药市场的预期成长率是多少
  • 推动全球抗风湿药物市场的关键因素是什么
  • COVID-19 对全球抗风湿药市场有何影响
  • 全球抗风湿药市场按类型划分是怎样的
  • 根据药物类别，全球抗风湿药市场的细分如何
  • 从给药途径来看，全球抗风湿药市场的细分是怎么样的
  • 从配销通路来看，全球抗风湿药市场的细分如何
  • 全球抗风湿药市场的重点区域有哪些
  • 10. 全球抗风湿药市场的主要参与者/公司有哪些？

本报告回答的关键问题

  • 2022年全球抗风湿药市场规模有多大？
  • 2023-2028年全球抗风湿药市场的预期成长率是多少？
  • 推动全球抗风湿药市场的关键因素是什么？
  • COVID-19 对全球抗风湿药市场有何影响？
  • 全球抗风湿药市场按类型划分是怎样的？
  • 根据药物类别，全球抗风湿药市场的细分如何？
  • 根据给药途径，全球抗风湿药物市场的细分如何？
  • 基于配销通路的全球抗风湿药市场的细分情况如何？
  • 全球抗风湿药市场的重点区域有哪些？
  • 全球抗风湿药市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球抗风湿药市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：按类型分類的市场细分

  • 处方药
    • 市场走向
    • 市场预测
  • 非处方药物
    • 市场走向
    • 市场预测

第 7 章：按药物类别分類的市场细分

  • 疾病缓解抗风湿药物 (DMARD)
    • 市场走向
    • 市场预测
  • 非类固醇类抗发炎药 (NSAID)
    • 市场走向
    • 市场预测
  • 皮质类固醇
    • 市场走向
    • 市场预测
  • 降尿酸药物
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：依药品管理途径分類的市场区隔

  • 口服
    • 市场走向
    • 市场预测
  • 注射用
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：按配销通路分類的市场区隔

  • 医院药房
    • 市场走向
    • 市场预测
  • 零售药局
    • 市场走向
    • 市场预测
  • 电子商务
    • 市场走向
    • 市场预测

第 10 章：按地区分類的市场细分

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 按国家/地区分類的市场细分
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca plc
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • Celltrion Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson & Johnsons
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112023A4148

Abstract

The global anti-rheumatics market size reached US$ 62.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 73.9 Billion by 2028, exhibiting a growth rate (CAGR) of 2.75% during 2022-2028. The increasing aging population across the globe, expansion of hospitals, clinics, and other healthcare facilities, and the expanding partnerships between large pharmaceutical companies and healthcare centers are some of the major factors propelling the market growth.

Anti-rheumatics are medications used to treat diseases affecting the joints, muscles, and connective tissues. They help reduce inflammation, pain, and stiffness, and slow the progression of the disease. They are available in various classes, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and biologics. They can be administered orally, subcutaneously and intravenously into the body. They target the underlying mechanisms that lead to tissue damage and inflammation. They are generally prescribed after a thorough diagnosis and are used in combination for optimum results.

The rising prevalence of rheumatic diseases due to unhealthy dietary patterns and lack of physical activity represent one of the key factors catalyzing the demand for effective treatments. Additionally, continuous development in drug delivery systems, like nanoparticle-based carriers or time-release capsules, is enhancing the efficacy and convenience of anti-rheumatic medications. Apart from this, the growth of telehealth services is enabling better disease management and easier prescription refills, promoting consistent use of anti-rheumatic drugs. Furthermore, the expansion of healthcare systems into emerging markets is making anti-rheumatic medications more accessible to underserved populations. Moreover, advancements in genomics and personalized medicine are allowing for more targeted treatments and improving the effectiveness of anti-rheumatic medications.

Anti-Rheumatics Market Trends/Drivers:

Rising aging population

The increasing aging population, which is more susceptible to joint disorders, such as osteoarthritis and rheumatoid arthritis, represents one of the key factors augmenting the market growth. Moreover, older populations often have multiple health conditions that can exacerbate rheumatic diseases, thus requiring more complex and long-term treatment strategies. Additionally, governing authorities and healthcare systems of various countries are recognizing this growing need and are increasing healthcare budgets to address the challenges of an aging society. Pharmaceutical companies are also focusing their research and development efforts on creating more effective and safer anti-rheumatic medications. As a result, the market for these drugs is expected to grow substantially in the coming years.

Strategic collaborations and mergers

The increasing number of strategic collaborations, mergers, and acquisitions (M&A) among pharmaceutical companies and healthcare facilities is another major factor contributing to the market growth. They often include knowledge-sharing agreements, making it easier to navigate regulatory hurdles and reducing the time-to-market for new medications. Additionally, the expanding partnerships between large pharmaceutical companies and biotech startups result in the faster development and commercialization of new anti-rheumatic drugs. Apart from this, it facilitates research and development (R&D) activities to introduce more advanced drugs. Furthermore, these collaborations promote an easy supply of anti-rheumatic drugs to reach previously untapped markets, contributing to global market growth.

Rising awareness about early diagnosis and prevention

The rising awareness among individuals about the benefits of early diagnosis and prevention of rheumatoid diseases is strengthening the growth of the market. Early diagnosis allows for more effective management of the disease, often requiring the use of anti-rheumatic drugs. Additionally, the increasing reliance of people on social media channels promoting medical education is positively influencing the market. Furthermore, the governing authorities of several countries are organizing public health campaigns, which is offering a favorable market outlook. Moreover, the development of advanced diagnostic tools has made it easier for healthcare professionals to identify rheumatic diseases at an early stage. This proactive approach enhances the market demand for anti-rheumatics, as timely intervention necessitates medication for symptom management and disease modification.

Anti-Rheumatics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market report, along with forecasts at the global regional, and country levels from 2023-2028. Our report has categorized the market based on type, drug class, route of drug administration and, distribution channel.

Breakup by Type:

Prescription-based Drugs

Over-the-Counter Drugs

Prescription-based drugs account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes prescription-based drugs and over-the-counter drugs. According to the report, prescription-based drugs represented the largest segment as they are usually more potent and targeted compared to over the counter (OTC) options. Additionally, prescription- based medications are generally more likely to be covered by insurance plans, making them financially accessible for a larger patient population. The ease of insurance claims for prescription drugs further promotes their usage and contributes to their larger market share. Apart from this, they come with the advantage of regular healthcare provider reviews, allowing for ongoing adjustments to the treatment regimen based on the course of the diseases and patient response. Furthermore, the latest innovations in anti-rheumatic treatments are often patented prescription medications. Pharmaceutical companies invest significantly in R&D to develop novel prescription drugs, ensuring that the most advanced treatment options are primarily available in prescription form.

Breakup by Drug Class:

Disease Modifying Anti-Rheumatics Drugs (DMARD's)

Nonsteroidal Anti-Inflammatory Drugs (NSAID's)

Corticosteroids

Uric Acid Drugs

Others

Disease modifying anti-rheumatics drugs (DMARD's) hold the largest share in the industry

A detailed breakup and analysis of the market based on the drug class has also been provided in the report. This includes disease modifying anti-rheumatics drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, uric acid drugs, and others. According to the report, disease modifying anti-rheumatics drugs (DMARD's) accounted for the largest market share as they work at a cellular level to modulate the immune response and aid in effectively altering the course of rheumatic diseases. Additionally, they help reduce the frequency of hospital visits, surgeries, and other expensive medical interventions. Apart from this, in many healthcare systems, DMARDs are included in insurance coverage plans, making them financially accessible to a larger population. Effective reimbursement policies further encourage the prescription of DMARDs, thus enhancing their market share. Moreover, continuous advancements in personalized medicine are leading to the development of more targeted DMARD therapies, enhancing their efficacy and reducing potential side effects, thereby reinforcing their market dominance.

Breakup by Route of Drug Administration:

Oral

Parenteral

Others

Parenteral represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the route of drug administration. This includes oral, parenteral, and others. According to the report, parenteral represented the largest segment as it allows for the direct delivery of drug into the bloodstream or target tissue, bypassing the gastrointestinal system. This results in a quicker onset of action and often increased efficacy compared to oral medications, which is a crucial factor in treating acute flare-ups or severe cases of rheumatic diseases. Apart from this, physicians often prefer parenteral administration for its rapid action, especially in hospital settings where immediate symptom relief or disease control is required. Moreover, parenteral medications undergo stringent quality control measures to ensure sterility and potency, which adds another layer of assurance for both healthcare providers and patients. Furthermore, many parenteral formulations are available in pre-filled syringes or auto-injectors, making it easier for patients to self-administer their medication, thereby enhancing adherence to treatment plans.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

E-Commerce

Hospital pharmacies exhibit a clear dominance in the market

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and e-commerce. According to the report, hospital pharmacies hold the majority of the market share as they are generally situated in close proximity to consultation rooms, diagnostic services, and treatment areas. This centralization allows for the immediate dispensing of anti-rheumatic medications following a diagnosis or prescription revision, providing an advantage in terms of convenience and speed over retail or online pharmacies. Additionally, pharmacists in hospital settings often have specialized training and experience in managing chronic diseases, including rheumatic conditions. They work in close collaboration with healthcare teams, including rheumatologists and nurses, ensuring that patients receive the most appropriate medication for their condition. Apart from this, they operate round-the-clock, ensuring that medications are available during emergencies or off-hours.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest anti-rheumatics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share since the region is a hub for pharmaceutical research and development (R&D). Additionally, North America, particularly the United States, has a well-established healthcare system equipped with state-of-the-art medical facilities. This superior infrastructure allows for the early diagnosis and comprehensive treatment of rheumatic diseases, which naturally leads to a higher demand for anti-rheumatic medications. Along with this, the widespread availability of specialized rheumatology clinics and medical professionals further drives the need for these drugs. Apart from this, the regulatory environment in North America, led by agencies like the U.S. Food and Drug Administration (FDA), is highly supportive of medical advancements. Furthermore, the increasing aging population in the region is driving the demand for anti-rheumatics.

Competitive Landscape:

Companies are investing heavily in the development of new anti-rheumatic drugs, targeting existing and emerging therapeutic mechanisms. Additionally, many companies are entering into partnerships, mergers, and acquisitions. These strategic collaborations often involve sharing technology, resources, and market channels. Apart from this, they are also focusing on expanding market access through various channels. This often involves launching products in new geographical markets, increasing production capacities, or diversifying supply chains to ensure more reliable distribution. Furthermore, various companies are using analytics to identify market trends, patient preferences, and treatment outcomes. Moreover, they are investing in educational programs for healthcare providers, patients, and the public.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

Amgen Inc.

AstraZeneca plc

Biogen Inc.

Bristol-Myers Squibb Company

Celltrion Inc.

Eli Lilly and Company

F. Hoffmann-La Roche AG

Johnson & Johnsons

Pfizer Inc.

Sanofi SA

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Recent Developments:

In July 2023, AbbVie Inc. announced that the first patient has been dosed in the Phase 3 Step-Up HS study to evaluate upadacitinib (RINVOQ®) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS) symptoms and have failed anti-tumor necrosis factor (TNF) therapy and one approved non-anti-TNF inhibitor therapy for HS.1

In November 2022, Amgen Inc. announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR).

In September 2022, Biogen Inc. announced that the European Medicines Agency (EMA) had accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody.

Key Questions Answered in This Report

  • 1. What was the size of the global anti-rheumatics market in 2022?
  • 2. What is the expected growth rate of the global anti-rheumatics market during 2023-2028?
  • 3. What are the key factors driving the global anti-rheumatics market?
  • 4. What has been the impact of COVID-19 on the global anti-rheumatics market?
  • 5. What is the breakup of the global anti-rheumatics market based on the type?
  • 6. What is the breakup of the global anti-rheumatics market based on the drug class?
  • 7. What is the breakup of the global anti-rheumatics market based on the route of drug administration?
  • 8. What is the breakup of the global anti-rheumatics market based on the distribution channel?
  • 9. What are the key regions in the global anti-rheumatics market?
  • 10. Who are the key players/companies in the global anti-rheumatics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Rheumatics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Prescription-based Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Over-the-Counter Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Disease Modifying Anti-Rheumatics Drugs (DMARD's)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAID's)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Corticosteroids
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Uric Acid Drugs
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Route of Drug Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Parenteral
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 E-Commerce
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Amgen Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Biogen Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bristol-Myers Squibb Company
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Celltrion Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Eli Lilly and Company
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 F. Hoffmann-La Roche AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
    • 15.3.9 Johnson & Johnsons
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sanofi SA
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Anti-Rheumatics Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Rheumatics Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Anti-Rheumatics Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Anti-Rheumatics Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Anti-Rheumatics Market: Breakup by Drug Class (in %), 2022
  • Figure 6: Global: Anti-Rheumatics Market: Breakup by Route of Drug Administration (in %), 2022
  • Figure 7: Global: Anti-Rheumatics Market: Breakup by Distribution Channel (in %), 2022
  • Figure 8: Global: Anti-Rheumatics Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Anti-Rheumatics (Prescription-based Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Anti-Rheumatics (Prescription-based Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Anti-Rheumatics (Over-the-Counter Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Anti-Rheumatics (Over-the-Counter Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Anti-Rheumatics (Disease Modifying Anti-Rheumatics Drugs (DMARD's)) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Anti-Rheumatics (Disease Modifying Anti-Rheumatics Drugs (DMARD's)) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Anti-Rheumatics (Nonsteroidal Anti-Inflammatory Drugs (NSAID's)) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Anti-Rheumatics (Nonsteroidal Anti-Inflammatory Drugs (NSAID's)) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Anti-Rheumatics (Corticosteroids) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Anti-Rheumatics (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Anti-Rheumatics (Uric Acid Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Anti-Rheumatics (Uric Acid Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Anti-Rheumatics (Other Drug Classes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Anti-Rheumatics (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Anti-Rheumatics (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Anti-Rheumatics (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Anti-Rheumatics (Parenteral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Anti-Rheumatics (Parenteral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Anti-Rheumatics (Other Routes of Drug Administration) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Anti-Rheumatics (Other Routes of Drug Administration) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Anti-Rheumatics (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Anti-Rheumatics (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Anti-Rheumatics (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Anti-Rheumatics (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Anti-Rheumatics (E-Commerce) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Anti-Rheumatics (E-Commerce) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: North America: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: North America: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: United States: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: United States: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Canada: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Canada: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Asia-Pacific: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Asia-Pacific: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: China: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: China: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Japan: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Japan: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: India: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: India: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: South Korea: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: South Korea: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Australia: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Australia: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Indonesia: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Indonesia: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Others: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Others: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Europe: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Europe: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Germany: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Germany: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: France: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: France: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: United Kingdom: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: United Kingdom: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Italy: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Italy: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Spain: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Spain: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Russia: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Russia: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Others: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Others: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Latin America: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Latin America: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Brazil: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Brazil: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Mexico: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Mexico: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Others: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: Others: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Middle East and Africa: Anti-Rheumatics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: Middle East and Africa: Anti-Rheumatics Market: Breakup by Country (in %), 2022
  • Figure 83: Middle East and Africa: Anti-Rheumatics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 84: Global: Anti-Rheumatics Industry: SWOT Analysis
  • Figure 85: Global: Anti-Rheumatics Industry: Value Chain Analysis
  • Figure 86: Global: Anti-Rheumatics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Rheumatics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Anti-Rheumatics Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Anti-Rheumatics Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 4: Global: Anti-Rheumatics Market Forecast: Breakup by Route of Drug Administration (in Million US$), 2023-2028
  • Table 5: Global: Anti-Rheumatics Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 6: Global: Anti-Rheumatics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Anti-Rheumatics Market: Competitive Structure
  • Table 8: Global: Anti-Rheumatics Market: Key Players